Oba01
Phase 1Small molecule
Oba01 is one of 49 small molecule programs targeting NSCLC. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
57 competitors in NSCLC
#DrugCompanyPhaseTrials
1Iressa
AstraZenecaApproved
Keytruda
Merck & Co.Phase 3
Taxotere
AAvyxa
Phase 3
Alimta
SShawn Eagle
Phase 3
Navmi
SSummit Therapeutics
Phase 3
Taxol
TevaPhase 2
Tecentriq
RochePhase 2
Alecensa
RochePhase 2
Libtayo
RegeneronPhase 2
SYS6010
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oba01. EMBL-EBI & Wellcome Sanger Institute.
- [4]